SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...

The presumed "cardioprotective" effect of beta blockers in patients without MI did not have an evidence base and was an extrapolation from heart failure trials and older post-MI trials.

Cardioprotective effects of lysyl oxidase inhibition Date: March 31, 2016 Source: Society for Experimental Biology and Medicine Summary: The collagen cross-linking enzyme, lysyl oxidase (LOX), is ...

Several experimental and numerous clinical studies have examined the cardioprotective potential of therapy with glucose, insulin, and potassium administered as an adjunct to myocardial reperfusion ...

Cardiovascular Outcome Trial-based, guideline-directed treatments using these drugs offer the promise of substantial cardioprotective benefit when used in appropriate patients in a timely fashion.

Protein with cardioprotective capabilities during heart attack discovered. ScienceDaily . Retrieved June 3, 2025 from www.sciencedaily.com / releases / 2010 / 11 / 101116103624.htm ...

Heart failure is a progressive condition, where structural and functional alterations of the ventricle limit the ability of the heart to either fill or eject blood. There are approximately 550,000 ...

Neurohormonal blockade using candesartan and/or metoprolol for women undergoing treatment for early breast cancer was not significantly protective against minor long-term decline in left ...

Four cardioprotective medications – aspirin, RAASi, statins, and metformin, were separately assessed as predictor variables. Individuals with an active prescription of any of these medicines, ...

Although cancer is associated with increased cardiovascular disease (CVD) risk, cancer survivors are less likely to receive cardioprotective therapies to mitigate this risk, according to a cross ...